Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

Sponsor
SWOG Cancer Research Network
Study ID
NCT07498205
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Myelofibrosis
  • Myelofibrosis (MF)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Momelotinib — DRUG
    200 mg daily x 96 weeks.
  • Ruxolitinib — DRUG
    Twice daily per treating investigator discretion not to exceed protocol specified guidelines.

Study Details

The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.

Key Dates

Start date
Aug 8, 2026
Status verified
Mar 2026
Primary completion
Aug 8, 2029
Completion
Aug 8, 2031

Study Design

Enrollment
268 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Momelotinib
    Momelotinib
  • Active Comparator: Ruxolitinib
    Ruxolitinib

Primary Outcome Measure

To estimate and compare the proportion of participants achieving a dual response [SVR35] and transfusion independence response from red blood cell transfusions. [ Time Frame: 24 weeks after randomization ]

Central Contacts

  • SWOG Clinical Trials Partnerships SWOG Clinical Trials Partnerships
    210-614-8808
    [email protected]

Related Studies